Among the drugs that have been shown to slow the progression of chronic kidney disease are glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, renin-angiotensin system inhibitors, and, more recently, non-steroidal mineralocorticoid receptor antagonists. Here, GLP1R is linked to chronic kidney disease.